Clive A Holmes

List of Publications by Citations

Source: https://exaly.com/author-pdf/8138411/clive-a-holmes-publications-by-citations.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

46
papers

10,520
citations

h-index

49
g-index

49
ext. papers

13,567
ext. citations

10.8
avg, IF

L-index

#	Paper	IF	Citations
46	Neuroinflammation in Alzheimer's disease. <i>Lancet Neurology, The</i> , 2015 , 14, 388-405	24.1	2760
45	Meta-analysis of 74,046 individuals identifies 11 new susceptibility loci for Alzheimer's disease. Nature Genetics, 2013, 45, 1452-8	36.3	2714
44	Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. <i>Lancet, The</i> , 2008 , 372, 216-23	40	1140
43	Genetic meta-analysis of diagnosed Alzheimer's disease identifies new risk loci and implicates Alltau, immunity and lipid processing. <i>Nature Genetics</i> , 2019 , 51, 414-430	36.3	917
42	Microglial priming in neurodegenerative disease. <i>Nature Reviews Neurology</i> , 2014 , 10, 217-24	15	664
41	Validity of current clinical criteria for Alzheimer's disease, vascular dementia and dementia with Lewy bodies. <i>British Journal of Psychiatry</i> , 1999 , 174, 45-50	5.4	267
40	Common polygenic variation enhances risk prediction for Alzheimer's disease. <i>Brain</i> , 2015 , 138, 3673-84	111.2	227
39	Periodontitis and Cognitive Decline in Alzheimer's Disease. <i>PLoS ONE</i> , 2016 , 11, e0151081	3.7	181
38	Etanercept in Alzheimer disease: A randomized, placebo-controlled, double-blind, phase 2 trial. <i>Neurology</i> , 2015 , 84, 2161-8	6.5	147
37	Convergent genetic and expression data implicate immunity in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2015 , 11, 658-71	1.2	146
36	Lavender oil as a treatment for agitated behaviour in severe dementia: a placebo controlled study. <i>International Journal of Geriatric Psychiatry</i> , 2002 , 17, 305-8	3.9	120
35	Nursing home placement in the Donepezil and Memantine in Moderate to Severe Alzheimer's Disease (DOMINO-AD) trial: secondary and post-hoc analyses. <i>Lancet Neurology, The</i> , 2015 , 14, 1171-81	24.1	101
34	Keep music live: music and the alleviation of apathy in dementia subjects. <i>International Psychogeriatrics</i> , 2006 , 18, 623-30	3.4	97
33	Determining the minimum clinically important differences for outcomes in the DOMINO trial. <i>International Journal of Geriatric Psychiatry</i> , 2011 , 26, 812-7	3.9	96
32	Gene-wide analysis detects two new susceptibility genes for Alzheimer's disease. <i>PLoS ONE</i> , 2014 , 9, e94661	3.7	90
31	Targeting innate immunity for neurodegenerative disorders of the central nervous system. <i>Journal of Neurochemistry</i> , 2016 , 138, 653-93	6	87
30	Peripheral inflammatory cytokines and immune balance in Generalised Anxiety Disorder: Case-controlled study. <i>Brain, Behavior, and Immunity</i> , 2017 , 62, 212-218	16.6	86

29	Genotype and phenotype in Alzheimer's disease. British Journal of Psychiatry, 2002, 180, 131-4	5.4	78
28	Long-term cognitive and functional decline in late onset Alzheimer's disease: therapeutic implications. <i>Age and Ageing</i> , 2003 , 32, 200-4	3	59
27	Role of infection in the pathogenesis of Alzheimer's disease: implications for treatment. <i>CNS Drugs</i> , 2009 , 23, 993-1002	6.7	52
26	Systemic inflammation and Alzheimer's disease. <i>Biochemical Society Transactions</i> , 2011 , 39, 898-901	5.1	51
25	Depression in Alzheimer's disease: the effect of serotonin receptor gene variation. <i>American Journal of Medical Genetics Part A</i> , 2003 , 119B, 40-3		43
24	Core outcome measures for interventions to prevent or slow the progress of dementia for people living with mild to moderate dementia: Systematic review and consensus recommendations. <i>PLoS ONE</i> , 2017 , 12, e0179521	3.7	36
23	The Edinburgh Consensus: preparing for the advent of disease-modifying therapies for Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017 , 9, 85	9	36
22	Cost-effectiveness of donepezil and memantine in moderate to severe Alzheimer's disease (the DOMINO-AD trial). <i>International Journal of Geriatric Psychiatry</i> , 2017 , 32, 1205-1216	3.9	32
21	Systemic infection modifies the neuroinflammatory response in late stage Alzheimer's disease. <i>Acta Neuropathologica Communications</i> , 2018 , 6, 88	7.3	32
20	Alzheimer's disease polygenic risk score as a predictor of conversion from mild-cognitive impairment. <i>Translational Psychiatry</i> , 2019 , 9, 154	8.6	31
19	New insights into the genetic etiology of Alzheimer's disease and related dementias <i>Nature Genetics</i> , 2022 ,	36.3	27
18	Common variants in Alzheimer's disease and risk stratification by polygenic risk scores. <i>Nature Communications</i> , 2021 , 12, 3417	17.4	23
17	Development of a core outcome set for disease modification trials in mild to moderate dementia: a systematic review, patient and public consultation and consensus recommendations. <i>Health Technology Assessment</i> , 2017 , 21, 1-192	4.4	19
16	Microglial motility in Alzheimer's disease and after AII2 immunotherapy: a human post-mortem study. <i>Acta Neuropathologica Communications</i> , 2019 , 7, 174	7.3	18
15	Effect of amyloid-[[A]]immunization on hyperphosphorylated tau: a potential role for glycogen synthase kinase (GSK)-3[[Neuropathology and Applied Neurobiology, 2015, 41, 445-57	5.2	17
14	Downregulated apoptosis and autophagy after anti-Allmmunotherapy in Alzheimer's disease. <i>Brain Pathology</i> , 2018 , 28, 603-610	6	12
13	Gene-based analysis in HRC imputed genome wide association data identifies three novel genes for Alzheimer's disease. <i>PLoS ONE</i> , 2019 , 14, e0218111	3.7	12
12	Reply to Bpecificity of mechanisms for plaque removal after Allmmunotherapy for Alzheimer diseasell <i>Nature Medicine</i> , 2004 , 10, 118-119	50.5	11

11	The clinical phenotype of familial and sporadic late onset Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2002 , 17, 146-9	3.9	10
10	The Locus Coeruleus in Aging and Alzheimer's Disease: A Postmortem and Brain Imaging Review. Journal of Alzheimer's Disease, 2021 , 83, 5-22	4.3	10
9	Neuroinflammation in dementia with Lewy bodies: a human post-mortem study. <i>Translational Psychiatry</i> , 2020 , 10, 267	8.6	9
8	A case-control study of the locus coeruleus degeneration in Alzheimer's disease. <i>European Neuropsychopharmacology</i> , 2021 , 43, 153-159	1.2	7
7	Psychological stress, cognitive decline and the development of dementia in amnestic mild cognitive impairment. <i>Scientific Reports</i> , 2020 , 10, 3618	4.9	6
6	Peripheral immunophenotype in dementia with Lewy bodies and Alzheimer's disease: an observational clinical study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020 , 91, 1219-1226	5.5	6
5	A randomised controlled trial of calcium channel blockade (CCB) with Amlodipine For the treatment oF subcortical ischaEmic vasCular demenTia (AFFECT): study protocol. <i>Trials</i> , 2016 , 17, 324	2.8	5
4	Intravenous immunoglobulin for Alzheimer's disease. <i>Lancet Neurology, The</i> , 2013 , 12, 218-9	24.1	4
3	Contribution of Genetics to the Understanding of Behavioral and Psychological Symptoms of Dementia. <i>International Psychogeriatrics</i> , 2000 , 12, 83-88	3.4	3
2	Exome sequencing identifies rare damaging variants in the ATP8B4 and ABCA1 genes as novel risk factors for Alzheimer Disease		1

EMERGING CONCEPTS IN BASIC SCIENCE: PANEL SESSION **2017**, 13, P1224